<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">716277</article-id><article-id pub-id-type="doi">10.17816/pmj43350-58</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Non-alcoholic fatty liver disease as a leading metabolic risk factor for severe COVID-19: a gender analysis</article-title><trans-title-group xml:lang="ru"><trans-title>Неалкогольная жировая болезнь печени как ведущий метаболический фактор риска тяжелого течения COVID-19: гендерный анализ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8394-5453</contrib-id><name-alternatives><name xml:lang="en"><surname>Abdurakhmаnov</surname><given-names>M. M.</given-names></name><name xml:lang="ru"><surname>Абдурахманов</surname><given-names>М. М.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>DSc in Medicine, Professor, Department of Surgical Diseases in Family Medicine</p></bio><bio xml:lang="ru"><p>доктор медицинcких наук, профессор кафедры хирургических болезней в семейной медицине</p></bio><email>hur-surg@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7587-6364</contrib-id><name-alternatives><name xml:lang="en"><surname>Tagaeva</surname><given-names>H. D.</given-names></name><name xml:lang="ru"><surname>Тагаева</surname><given-names>Х. Д.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>Assistant, Department of Infectious Diseases and Pediatric Infectious Diseases</p></bio><bio xml:lang="ru"><p>ассистент кафедры инфекционных болезней и детских инфекционных болезней</p></bio><email>hur-surg@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8807-3081</contrib-id><name-alternatives><name xml:lang="en"><surname>Oblokulov</surname><given-names>A. R.</given-names></name><name xml:lang="ru"><surname>Облокулов</surname><given-names>А. Р.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>DSc in Medicine, Professor, Department of Infectious Diseases and Pediatric Infectious Diseases</p></bio><bio xml:lang="ru"><p>доктор медицинcких наук, профессор кафедры инфекционных болезней и детских инфекционных болезней</p></bio><email>hur-surg@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9498-4335</contrib-id><name-alternatives><name xml:lang="en"><surname>Umedov</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Умедов</surname><given-names>Х. А.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>PhD in Medicine, Assistant, Department of Surgical Diseases No. 2</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, ассистент кафедры хирургических болезней № 2</p></bio><email>hur-surg@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0444-9791</contrib-id><name-alternatives><name xml:lang="en"><surname>Abdurakhmanov</surname><given-names>Z. M.</given-names></name><name xml:lang="ru"><surname>Абдурахманов</surname><given-names>З. М.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>PhD in Medicine, Associate Professor, Department of Surgical Diseases in Family Medicine</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры хирургических болезней в семейной медицине</p></bio><email>hur-surg@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Bukhara State Medical Institute named after Abu Ali ibn Sino</institution></aff><aff><institution xml:lang="ru">Бухарский государственный медицинский институт имени Абу Али ибн Сина</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Samarkand State Medical University</institution></aff><aff><institution xml:lang="ru">Самаркандский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-07-10" publication-format="electronic"><day>10</day><month>07</month><year>2026</year></pub-date><volume>43</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>50</fpage><lpage>58</lpage><history><date date-type="received" iso-8601-date="2026-07-09"><day>09</day><month>07</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-07-09"><day>09</day><month>07</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/716277">https://permmedjournal.ru/PMJ/article/view/716277</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> To evaluate the sex-related association between non-alcoholic fatty liver disease (NAFLD) and COVID-19 severity, and to assess the impact of metabolic syndrome components on the risk of severe disease.</p> <p><bold>Materials and methods.</bold> A retrospective analysis was conducted on 105 patients hospitalized with COVID-19 at the Bukhara Regional Infectious Diseases Hospital between September 2020 and September 2022. The diagnosis of non-alcoholic fatty liver disease (NAFLD) was established based on computed tomography (CT) or medical history. The study group included 55 patients with COVID-19 and NAFLD, while 50 patients with COVID-19 without NAFLD served as the control group. Multivariate logistic regression analysis was performed to evaluate predictors of severe COVID-19, adjusting for age, sex, body mass index (BMI), smoking, and components of metabolic syndrome.</p> <p><bold>Results.</bold> Severe COVID-19 occurred significantly more often in patients with NAFLD compared to those without NAFLD (34.5 vs. 18.0 %; <italic>p</italic> = 0.001). NAFLD and smoking were identified as the strongest independent predictors of severe disease. Women with NAFLD exhibited a higher risk of severe COVID-19 (odds ratio (OR) 4.17; 95 % CI 4.08–4.58; <italic>p</italic> = 0.001) compared to men (OR 3.18; 95 % CI 3.10–3.69; <italic>p</italic> = 0.004), whereas type 2 diabetes mellitus (T2DM) had minimal impact on this risk in women compared to men (OR 0.95; 95 % CI 0.84–1.09; <italic>p</italic> = 0.04). Obesity and metabolic syndrome were also independent predictors of severe disease in both sexes.</p> <p><bold>Conclusions.</bold> NAFLD is an independent risk factor for severe COVID-19 in both sexes, with a more pronounced risk in women. These findings underscore the importance of a comprehensive management approach for patients with COVID-19 that considers underlying NAFLD and metabolic abnormalities. Further large-scale prospective studies are needed to clarify the mechanisms underlying this association.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Оценить гендерную взаимосвязь между неалкогольной жировой болезнью печени (НАЖБП) и тяжестью течения COVID-19, а также изучить влияние компонентов метаболического синдрома на риск тяжелого заболевания.</p> <p><bold>Материалы и методы. </bold>Проведен ретроспективный анализ 105 пациентов, госпитализированных в Бухарскую областную инфекционную больницу с COVID-19 в период с сентября 2020 г. по сентябрь 2022 г. Диагноз неалкогольной жировой болезни печени (НАЖБП) выставлялся на основании компьютерной томографии (КТ) или данных анамнеза. Основная группа включала 55 пациентов с COVID-19 и НАЖБП, контрольная – 50 пациентов с COVID-19 без НАЖБП. Для оценки предикторов тяжелого течения COVID-19 использовался многовариантный логистический регрессионный анализ с корректировкой на возраст, пол, индекс массы тела (ИМТ), курение и компоненты метаболического синдрома.</p> <p><bold>Результаты.</bold> Тяжелое течение COVID-19 отмечено значительно чаще у пациентов с НАЖБП по сравнению с таковым у пациентов без НАЖБП (34,5 против 18,0 %; <italic>p</italic> = 0,001). НАЖБП и курение оказались наиболее сильными независимыми предикторами тяжелого течения заболевания. Женщины с НАЖБП демонстрировали более высокий риск тяжелого течения COVID-19 (отношение шансов (ОШ) 4,17; 95 % ДИ 4,08–4,58; <italic>p</italic> = 0,001) по сравнению с мужчинами (ОШ 3,18; 95 % ДИ 3,10–3,69; <italic>p</italic> = 0,004), в то время как сахарный диабет 2-го типа (СД) оказал минимальное влияние на этот риск у женщин по сравнению с мужчинами (ОШ 0,95; 95 % ДИ 0,84–1,09; <italic>p</italic> = 0,04). Независимыми предикторами тяжелого течения также являлись ожирение и метаболический синдром у обоих полов.</p> <p><bold>Выводы.</bold> НАЖБП является независимым фактором риска тяжелого течения COVID-19 у обоих полов, при этом у женщин этот риск более выражен. Полученные данные подчеркивают важность комплексного подхода к ведению пациентов с COVID-19 с учетом сопутствующих НАЖБП и метаболических нарушений. Для уточнения механизмов этой взаимосвязи необходимы дальнейшие крупномасштабные проспективные исследования.</p></trans-abstract><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>COVID-19</kwd><kwd>smoking</kwd><kwd>metabolic syndrome</kwd><kwd>obesity</kwd><kwd>risk factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>COVID-19</kwd><kwd>курение</kwd><kwd>метаболический синдром</kwd><kwd>ожирение</kwd><kwd>факторы риска</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ahmed A., Wong R.J., Harrison S.A. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015; 13: 2062–2070. DOI: 10.1016/j.cgh.2015.07.029</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gao F., Zheng K.I., Wang X.B., et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020; 43: 72–74. DOI: 10.2337/dc20-0682</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Abd El-Kader S.M., El-Den Ashmawy E.M. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015; 7: 846–858. DOI: 10.4254/wjh.v7.i6.846</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Younossi Z.M., Blissett D., Blissett R., et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64: 1577–1586. DOI: 10.1002/hep.28785</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lee C.H., Choi S.H., Chung G.E., et al. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int. 2018; 38: 2091–2100. DOI: 10.1111/liv.13860</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Nseir W.B., Mograbi J.M., Amara A.E., et al. Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia. QJM 2019; 112: 95–99. DOI: 10.1093/qjmed/hcy227</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pinchuk T.V., Orlova N.V., Suranova T.G., Bonkalo T.I. Mechanisms of liver damage in COVID 19. Medical Alphabet. 2020; (19): 39–46. DOI: 10.33667/2078-5631-2020-19-39-46</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Feng Y., Liu Y., Zhao Q., Zhu J., Kang X., Mi C., Li P., Li W., Lu G., Jia A., He S., Li H. Liver Injury in Patients with COVID-19: A Retrospective Study. Int J Med Sci. 2023; 20 (3): 385–391. DOI: 10.7150/ijms.81214</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Vinokurov A.S., Nikiforova M.V., Oganesyan A.A., Vinokurova O.O., Yudin A.L., Yumatova E.A. COVID-19. Liver damage – visualization features and possible causes. Medical Visualization 2020; 24 (3): 26–36. DOI: 10.24835/1607-0763-2020-3-26-36</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zheng K.I., Gao F., Wang X.B., et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism 2020; 108: 154244. DOI: 10.1016/j.metabol.2020.154244</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zou Z.Y., Wong V.W., Fan J.G. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of prevalence, genetic, metabolic and histological profiles. J Dig Dis. 2020; 21 (7): 372–384. DOI: 10.1111/1751-2980.12871</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chai X., Hu L., Zhang Y., et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. DOI: 10.1101/2020.02.03.931766</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cheong J. et al. Gastrointestinal and liver manifestations of COVID 19. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association 2020; 26 (5): 226–232. DOI: 10.4103/sjg.SJG_147_20</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Li B., Yang J., Zhao F., et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109: 531–538. DOI: 10.1007/s00392-020-01626-9</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yanlan Xu, Xinyu Yang, Hua Bian, Mingfeng Xia. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids in Health and Disease 2021. 20: 126. 1–11. DOI: 10.1186/s12944-021-01564-z</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Wu J. et al. Liver diseases in COVID 19: Etiology, treatment and prognosis. World Journal of Gastroenterology 2020. 26 (19): 2286. DOI: 10.3748/wjg.v26.i19.2286</mixed-citation></ref></ref-list></back></article>
